Skip to content

BJCP article: Analysis examines safety of antidepressant use during pregnancy

Use of fluoxetine – the most commonly prescribed antidepressant – during pregnancy is linked with a slightly increased risk of malformations in infants, according to a recent analysis of published studies.

In the analysis of 16 studies, infants exposed to fluoxetine during the first trimester had an 18% increased relative risk of major malformations and a 36% increased relative risk of cardiovascular malformations. There were no significant observations of other system-specific malformations in the nervous system, eye, urogenital system, digestive system, respiratory system, or musculoskeletal system.

The findings are published in the British Journal of Clinical Pharmacology.

Similar research was published at an earlier time in the British Journal of Clinical Pharmacology

Latest news & activity

Prizes and awards

The International Union of Basic & Clinical Pharmacology (IUPHAR) have announced that Professor Michael Spedding is to receive its Lifetime…

Award

The British Pharmacological Society is delighted to announce the recipients of its 2026 PhD Funding, including the four inaugural winners of the Sir…

Press releases

 

The British Pharmacological Society’s recent position statement on medicines in pregnancy and breastfeeding has received strong national media…